Immune markers of disease severity and treatment response in pediatric acquired aplastic anemia

Pediatric Blood and Cancer

Volumn 60, Issue 3, 2013, Pages 455-460

  Sutton, Kathryn S ^a   Shereck, Evan B ^a   Nemecek, Eneida R ^a   Kurre, Peter ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Aplastic anemia; Immunosuppression; PNH clones

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; THYMOCYTE ANTIBODY;

ACQUIRED APLASTIC ANEMIA; ADOLESCENT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNITY; IMMUNOPHENOTYPING; LIVER DISEASE; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ANEMIA, APLASTIC; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IMMUNOPHENOTYPING; INFANT; KILLER CELLS, NATURAL; MALE; RETROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 84872444119     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24247     Document Type: Article

References (39)

1. Leguit RJ, Van Den Tweel JG. The pathology of bone marrow failure. Histopathology 2010; 57: 655-670.
2. Kagan WA, Ascensão JA, Pahwa RN, et al. Aplastic anemia: Presence in human bone marrow of cells that suppress myelopoiesis. Proc Natl Acad Sci USA 1976; 73: 2890-2894.
3. Brodsky RA, Jones RJ. Aplastic anemia. Lancet 2005; 365: 1647-1656.
4. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509-2519.
5. Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4+CD25+FoxP3+ T regulatory cells in acquired aplastic anemia. Blood 2007; 110: 1603-1606.
6. Wang XG, Cao YM, Wang XG. Detection and significance of CD4+ CD25int/high CD127low regulatory T cells in pediatric aplastic anemia. Chin J Contemp Pediatr 2011; 13: 292-295.
7. Wang XG, Wang XG, Luan B. et al. Expression of regulatory T cells and Foxp3 gene in peripheral blood of children with aplastic anemia. Chin J Contemp Pediatr 2010; 12: 241-243.
8. Yin XX, Liu CF, Li LZ, et al. Significance of CD4+ CD25+ CD127(low) regulatory T cells and notch1 pathway in the pathogenesis of aplastic anemia. Chin J Hematol 2008; 29: 308-311.
9. Kordasti S, Marsh J, Al-Khan S, et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood 2012; 119: 2033-2043.
10. Li ZS, Shao ZH, Fu R, et al. Percentages and functions of natural killer cell subsets in peripheral blood of patients with severe aplastic anemia. Chin Med J 2011; 91: 1084-1087.
11. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73: 703-711.
12. Pu JJ, Brodsky RA. Paroxysmal nocturnal hemoglobinuria from bench to bedside. Clin Transl Sci 2011; 4: 219-224.
13. Kinoshita T, Inoue N. Dissecting and manipulating the pathway for glycosyl-phosphatidylinositol-anchor biosynthesis. Curr Opin Chem Biol 2000; 4: 632-638.
14. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984; 160: 1558-1578.
15. Brodsky RA. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev 2008; 22: 65-74.
16. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144: 3478-3483.
17. Lewis SM, Dacie JV. The aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. Br J Haematol 1967; 85: 1354-1363.
18. Young NS. Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A mutant hematopoietic cells in bone marrow failure. Haematologica 2009; 94: 3-7.
19. Dunn D, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Int Med 1999; 131: 401-408.
20. Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002; 100: 3897-3902.
21. Sugimori C, Mochizuki K. Qi Z. et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure. Br J Haematol 2009; 147: 102-112.
22. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59-blood cells predicts response to immunosuppressive therapy and prognosis with aplastic anemia. Blood 2006; 107: 1308-1314.
23. Yoshida N, Yagasaki H, Takahashi Y, et al. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal hemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anemia. Br J Haematol 2008; 142: 427-435.
24. Ishiyama K, Chuhjo T, Wang H, et al. Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 2003; 102: 1211-1216.
25. Scheinberg P, Marte M, Nunez O, et al. Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine. Haematologica 2010; 95: 1075-1080.
26. Li Y, Li X, Ge M, et al. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience. Ann Hematol 2011; 90: 529-537.
27. Timeus F, Crescenzio N, Lorenzati A, et al. Paroxysmal nocturnal hemoglobinuria clones in children with acquired aplastic anemia: a prospective single centre study. Br J Haematol 2010; 150: 483-485.
28. Rosenfeld SJ, Kimball J, Vining D, et al. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85: 3058-3065.
29. Scheinberg P, Wu CO, Nunez O, et al. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr 2008; 153: 814-819.
30. De Mola RL, Kurre P, MRI findings in Aplastic Anemia. Am J Hematol 2009; 84: 754.
31. Wanachiwanawin W, Siripanyaphinyo U, Piyawattanasakul N, et al. A cohort study of the nature of paroxysmal nocturnal hemoglobinuria clones and PIG-A mutations in patients with aplastic anemia. Eur J Haematol 2006; 76: 502-509.
32. Pu JJ, Muhkina G, Wang H, et al. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. Eur J Haematol 2011; 87: 37-45.
33. Wang YX, Xu CG, Ran JL, et al. In vitro activation of bone marrow natural killer T cells of aplastic anemia. Chin J Hematol 2010; 31: 536-539.
34. Furher M, Burdach S, Ebell W, et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. Klinische Padiatrie 1998; 210: 173-179.
35. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000; 96: 2049-2054.
36. Sheinberg P, Wu CO, Nunez O, et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. British J Haematol 2008; 1144: 206-216.
37. Saracco P, Quarello P, Iori AP, et al. Cyclosporine A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol 2008; 140: 197-205.
38. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunol 2005; 6: 345-352.
39. Fujisaki J, Wu J, Carlson AL, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 2011; 474: 216-220.